peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Honors == Dr. Goldstein is the recipient of several awards, including the Career Scientist Award of the Health Research Council, City of New York; the Van Dyke Memorial Award in Pharmacology from the Columbia University College of Physicians and Surgeons; the Copernicus Medal from the University of Kraków; a citation from the U.S. Department of Health, Education and Welfare "in recognition and appreciation of outstanding work in helping to establish a national program on Biological Response Modifiers"; a Doctor of Science degree (honoris causa) from Wagner College; the Decoration of the Order of Vasco Núñez de Balboa, in the rank of Commander, Panama's highest honor, for "contributions directed to the preservation of human life in the world"; the Distinguished Researcher Award of the George Washington University School of Medicine, and the Chevalier des Palmes Académiques, the highest civilian award of France. He was elected to ΑΩΑ, the National Medical Honor Society in 2007.
=== Nobel Prizes for vitamin research === The Nobel Prize for Chemistry for 1928 was awarded to Adolf Windaus "for his studies on the constitution of the sterols and their connection with vitamins", the first person to receive an award mentioning vitamins, even though it was not specifically about vitamin D. The Nobel Prize in Physiology or Medicine for 1929 was awarded to Christiaan Eijkman and Frederick Gowland Hopkins for their contributions to the discovery of vitamins. Thirty-five years earlier, Eijkman had observed that chickens fed polished white rice developed neurological symptoms similar to those observed in military sailors and soldiers fed a rice-based diet, and that the symptoms were reversed when the chickens were switched to whole-grain rice. He called this "the anti-beriberi factor", which was later identified as vitamin B1, thiamine. In 1930, Paul Karrer elucidated the correct structure for beta-carotene, the main precursor of vitamin A, and identified other carotenoids. Karrer and Norman Haworth confirmed Albert Szent-Györgyi's discovery of ascorbic acid and made significant contributions to the chemistry of flavins, which led to the identification of lactoflavin. For their investigations on carotenoids, flavins and vitamins A and B2, they both received the Nobel Prize in Chemistry in 1937. In 1931, Albert Szent-Györgyi and a fellow researcher Joseph Svirbely suspected that "hexuronic acid" was actually vitamin C, and gave a sample to Charles Glen King, who proved its ability to counter scurvy in his long-established guinea pig scorbutic assay.
Austin had walked out of the company again, publicly stating he felt underwhelming storylines were presented to him by the creative team. For the remainder of 2002, Austin kept a low profile and did not make any public appearances. It was reported, however, by the end of the year, that Austin and McMahon met and resolved their differences. He then agreed to return to the company in early 2003. In an interview with WWE Raw Magazine, he announced deep regret over the situation that led to his departure and the manner in which he had left, and deeper regret over inaccurate speculation regarding his alleged grudges held against other WWE wrestlers, claiming he had no problem with Hall rejoining the company. However, he admitted he still held strong reservations about his singles match with Hall at WrestleMania only lasting seven minutes and felt the build-up to the match did not live up to the expectations of his fans or Hall's, and was angered by speculation suggesting he disagreed with Kevin Nash re-joining the company, insisting he and Nash have always been good friends. He did, however, maintain his displeasure with the storylines and creative changes the WWE had imposed around the time of his departure. In an interview with Vince McMahon on his podcast in 2014, Austin publicly revealed for the first time that McMahon had fined him $650,000 upon his return, but he was able to lower the amount to $250,000. Austin confessed he had a major rift with Triple H's role in the company upon his return in 2002 but insisted as of 2003, they resolved their issues.
Sutherland goes further to say that deviancy is contingent on conflicting groups within society, and that such groups struggle over the means to define what is criminal or deviant within society. Criminal organizations therefore gravitate around illegal avenues of production, profit-making, protectionism or social control and attempt (by increasing their operations or membership) to make these acceptable. This also explains the propensity of criminal organizations to develop protection rackets, to coerce through the use of violence, aggression and threatening behavior (at times termed 'terrorism'). Preoccupation with methods of accumulating profit highlight the lack of legitimate means to achieve economic or social advantage, as does the organization of white-collar crime or political corruption (though it is debatable whether these are based on wealth, power or both). The ability to effect social norms and practices through political and economic influence (and the enforcement or normalization of criminogenic needs) may be defined by differential association theory.
Sources: en.wikipedia.org
ILP solvers, such as CPLEX, can compute the exact optimal solution for large instances of protein design problems. These solvers use a linear programming relaxation of the problem, where qi and qij are allowed to take continuous values, in combination with a branch and cut algorithm to search only a small portion of the conformation space for the optimal solution. ILP solvers have been shown to solve many instances of the side-chain placement problem.
Elevated ITGA1 expression correlates with activation of survival pathways and is regulated through a non-coding RNA mechanism involving hsa_circ_0110757, which increases ITGA1 expression by suppressing hsa-miR-1298-5p.
In 1924, a 5-year-old girl from Föglö, Åland, Finland, was brought to the Deaconess Hospital in Helsinki, where she was seen by Finnish physician Erik Adolf von Willebrand. He ultimately assessed 66 members of her family and reported in a 1926 Swedish-language article that this was a previously undescribed bleeding disorder that differed from hemophilia. He published another article on the disorder in 1931, in the German language, which attracted international attention in the disease. The eponymous name was assigned to the disease between the late 1930s and the early 1940s, in recognition of von Willebrand's extensive research. In the 1950s, it became clear that a "plasma factor", factor VIII, was decreased in these persons and that Cohn fraction I-0 could correct both the plasma deficiency of FVIII and the prolonged bleeding time. Since this time, the factor causing the long bleeding time was called the "von Willebrand factor" in honor of Erik Adolf von Willebrand. Variant forms of VWF were recognized in the 1970s, and these variations are now recognized as the result of synthesis of an abnormal protein. During the 1980s, molecular and cellular studies distinguished hemophilia A and VWD more precisely. Persons who had VWD had a normal FVIII gene on the X chromosome, and some had an abnormal VWF gene on chromosome 12. Gene sequencing identified many of these persons as having a VWF gene mutation. The genetic causes of milder forms of low VWF are still under investigation, and these forms may not always be caused by an abnormal VWF gene.
== Related stain == Van Gieson’s solution is frequently used in combination with other stains for greater information. In the Hematoxylin–Van Gieson (HVG) method, an iron hematoxylin is applied first, staining nuclei dark blue, followed by Van Gieson’s solution. This results in dark nuclei, red collagen, and yellow cytoplasmic elements. In the Verhoeff–Van Gieson (VVG) stain, Verhoeff’s iron-hematoxylin (containing ferric chloride and iodine) is used first to stain elastic fibers black, then Van Gieson’s counterstain colors collagen red and cytoplasm yellow.
The wound is initially cleaned, debrided and observed, typically 4 or 5 days before closure. The wound is purposely left open. Examples: healing of wounds by use of tissue grafts. If the wound edges are not reapproximated immediately, delayed primary wound healing transpires. This type of healing may be desired in the case of contaminated wounds. By the fourth day, phagocytosis of contaminated tissues is well underway, and the processes of epithelization, collagen deposition, and maturation are occurring. Foreign materials are walled off by macrophages that may metamorphose into epithelioid cells, which are encircled by mononuclear leukocytes, forming granulomas. Usually the wound is closed surgically at this juncture, or the scab is eaten, and if the "cleansing" of the wound is incomplete, chronic inflammation can ensue, resulting in prominent scarring.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.